Data layers Raw facts Calculated Model prediction AI interpretation

IPO Timeline Raw facts

Broker Deadline
Morning deadline
HKEX Deadline
Noon deadline
Broker Results (T-2)
Some brokers release in afternoon
Grey Market (T-1)
Afternoon
HKEX Allotment (T-1)
Evening
Registrar Allotment (T-1)
Evening
Listing Day (T)
First day of trading

Cross-Market Price Comparison

Other Listed Market Shanghai (SSE) — 迈威生物
Other Market Stock Code688062
H-Share Offer PriceHK$ 27.64
Other Market PriceLoading...
Reference Exchange RateLoading...
H-Share Offer Price Premium/Discount vs Other MarketLoading...

Company Overview

Stock NameMabwell-B
Stock Code02493
Company Full NameMabwell (Shanghai) Bioscience Co., Ltd.
IndustryHealthcare
Principal ActivitiesWe are a Chinese pharmaceutical company known for our innovation capabilities in drug research and development as well as our end-to-end capabilities from drug discovery to commercialization. We primarily focus on the independent development of drugs in areas such as oncology, immunology, ophthalmology, and orthopedics. We have established a pipeline product portfolio comprising 4 marketed products and 10 drug candidates of different varieties (1 at the NDA stage, 8 at the clinical stage, and 1 at the preclinical stage), including a self-developed core product 9MW2821 (an ADC candidate targeting Nectin-4).
Listing Date2026-04-28
Listing Rules EraNew Rules (after Aug 2025)
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國上海市中國(上海)自由貿易試驗區蔡倫路230號2幢105室
Business Address (Hong Kong)香港銅鑼灣希慎道33號利園一期19樓1928室
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.mabwell.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingYes (A股)

Offering Information

Offering Mechanism Mechanism B
Offer PriceHK$ 27.64 / shares
Offer Price RangeFinal offer price only, no range
Lot Size200 shares
Entry ThresholdHK$ 5,528
Par ValueRMB 1.0 / shares
Offer Period2026-04-20 to 2026-04-23
Global Offering Shares47,130,200 shares
HK Public Offer Shares (Initial)4,713,200 shares (10.0%)
Public Offer Lots (Initial)23,566lots (Pool A11,783lots,Pool B11,783lots)
International Placing Shares (Initial)42,417,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO446,730,200 shares
Greenshoe (Over-allotment Option)No
Stabilizing Manager (Greenshoe)—
Cornerstone Share31.9%
Clawback TiersMechanism B: no clawback
Reallocation OptionNo
Total Global Offering SizeHK$ 1,302,678,728

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 200 HK$ 5,528
2 lots 400 HK$ 11,056
3 lots 600 HK$ 16,584
4 lots 800 HK$ 22,112
5 lots 1,000 HK$ 27,640
6 lots 1,200 HK$ 33,168
7 lots 1,400 HK$ 38,696
8 lots 1,600 HK$ 44,224
9 lots 1,800 HK$ 49,752
10 lots 2,000 HK$ 55,280
15 lots 3,000 HK$ 82,920
20 lots 4,000 HK$ 110,560
25 lots 5,000 HK$ 138,200
30 lots 6,000 HK$ 165,840
35 lots 7,000 HK$ 193,480
40 lots 8,000 HK$ 221,120
45 lots 9,000 HK$ 248,760
50 lots 10,000 HK$ 276,400
100 lots 20,000 HK$ 552,800
150 lots 30,000 HK$ 829,200
200 lots 40,000 HK$ 1,105,600
250 lots 50,000 HK$ 1,382,000
300 lots 60,000 HK$ 1,658,400
350 lots 70,000 HK$ 1,934,800
400 lots 80,000 HK$ 2,211,200
450 lots 90,000 HK$ 2,487,600
500 lots 100,000 HK$ 2,764,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1,000 lots 200,000 HK$ 5,528,000
1,500 lots 300,000 HK$ 8,292,000
2,000 lots 400,000 HK$ 11,056,000
2,500 lots 500,000 HK$ 13,820,000
3,000 lots 600,000 HK$ 16,584,000
3,500 lots 700,000 HK$ 19,348,000
4,000 lots 800,000 HK$ 22,112,000
4,500 lots 900,000 HK$ 24,876,000
5,000 lots 1,000,000 HK$ 27,640,000
10,000 lots 2,000,000 HK$ 55,280,000
11,783 lots 2,356,600 HK$ 65,136,424

Stock Connect Inclusion Analysis

HK Market Cap HK$ 953.5M
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)HK$ 12,347,622,728
H-Share Market Cap (at Offer Price)HK$ 1,302,678,728
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot applicable (loss-making)
Profit/Loss StatusNet loss RMB 972.3 million
Period-End Cash BalanceRMB 1,191.9 million
Listing Expenses~HK$ 119,400,000
Listing Expenses / Funds Raised~8.7%
Total Pre-IPO InvestmentTo be extracted
First Day CloseHK$ 27.8
First Day OpenHK$ 28.3
First Day Change0.58%
First Day Volume15006500.0
First Day Turnover424940000.0
Use of Proceeds
1、約56.8%,或713.0百萬港元將用于核心產品9MW2821針對多種適用癥不同階段的臨床開發試驗; 2、約17.7%,或222.3百萬港元將用于針對具有大量臨床需求的腫瘤和年齡相關疾病的其他管線產品的研發; 3、約15.5%,或194.7百萬港元將用于商業化目的; 4、約10.0%,或125.6百萬港元將用于營運資金及其他一般公司用途。

Underwriting Syndicate

Joint Sponsors (2)
中信证券(香港)有限公司 CE AAK249 海通国际资本有限公司 CE ADQ859
Sponsor cum Overall Coordinator (1)
CLSA LIMITED CE AAB893
Overall Coordinators (4)
CLSA LIMITED CE AAB893 海通国际证券有限公司 CE AAF806 CHINA INDUSTRIAL SECURITIES INTERNATIONAL CAPITAL LIMITED CE BAK956 招银国际融资有限公司 CE AVM940
Joint Global Coordinators (8)
CLSA LIMITED CE AAB893 海通国际证券有限公司 CE AAF806 CHINA INDUSTRIAL SECURITIES INTERNATIONAL CAPITAL LIMITED CE BAK956 招银国际融资有限公司 CE AVM940 建银国际金融有限公司 CE AJO225 Guosen Securities (HK) Brokerage Company, Limited CE AUI491 富途证券国际(香港)有限公司 CE AZT137 农银国际融资有限公司 CE AWL249
Joint Bookrunners (8)
CLSA LIMITED CE AAB893 海通国际证券有限公司 CE AAF806 CHINA INDUSTRIAL SECURITIES INTERNATIONAL CAPITAL LIMITED CE BAK956 招银国际融资有限公司 CE AVM940 建银国际金融有限公司 CE AJO225 Guosen Securities (HK) Brokerage Company, Limited CE AUI491 富途证券国际(香港)有限公司 CE AZT137 农银国际融资有限公司 CE AWL249
Joint Lead Managers (9)
CLSA LIMITED CE AAB893 海通国际证券有限公司 CE AAF806 CHINA INDUSTRIAL SECURITIES INTERNATIONAL CAPITAL LIMITED CE BAK956 招银国际融资有限公司 CE AVM940 建银国际金融有限公司 CE AJO225 Guosen Securities (HK) Brokerage Company, Limited CE AUI491 富途证券国际(香港)有限公司 CE AZT137 农银国际证券有限公司 CE ACX411 BOWLEA SECURITIES LIMITED CE BTJ616
Capital Market Intermediaries (10)
CLSA LIMITED CE AAB893 海通国际证券有限公司 CE AAF806 CHINA INDUSTRIAL SECURITIES INTERNATIONAL CAPITAL LIMITED CE BAK956 招银国际融资有限公司 CE AVM940 建银国际金融有限公司 CE AJO225 Guosen Securities (HK) Brokerage Company, Limited CE AUI491 富途证券国际(香港)有限公司 CE AZT137 农银国际融资有限公司 CE AWL249 农银国际证券有限公司 CE ACX411 BOWLEA SECURITIES LIMITED CE BTJ616

Service Providers

RoleInstitution
Legal Advisor to Company Davis Polk & Wardwell
竞天公诚律师事务所
霍金路伟律师行
Legal Advisor to Sponsors/Underwriters Herbert Smith Freehills Kramer
金杜律师事务所
Auditor and Reporting Accountant 安永会计师事务所
Industry Advisor 弗若斯特沙利文(北京)咨询有限公司上海分公司
Compliance Advisor Somerley Capital Limited CE BAU754
Receiving Banks 中国银行(香港)有限公司
招商永隆银行有限公司

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 君实香港 20,000,000 USD 5,668,200 12.03% 1.27% 6 months 2026-10-28
2 Sanjin International 15,000,000 USD 4,251,200 9.02% 0.95% 6 months 2026-10-28
3 国惠香港 7,000,000 USD 1,983,800 4.21% 0.44% 6 months 2026-10-28
4 昌荣国际 7,000,000 USD 1,983,800 4.21% 0.44% 6 months 2026-10-28
5 WuXi Biologics Venture 3,000,000 USD 850,200 1.80% 0.19% 6 months 2026-10-28
6 中和资本 1,000,000 USD 283,400 0.60% 0.06% 6 months 2026-10-28

Directors & Management

PositionChinese nameEnglish Name
Chairman劉大濤—
Company Secretary王鶴飛—
Executive Director唐春山TANG Chunshan
Non-Executive Director吴玉峰WU Yufeng
Independent Non-Executive Director秦正余QIN Zhengyu
Executive Director刘大涛LIU Datao
Independent Non-Executive Director许青XU Qing
Executive Director武海WU Hai
Independent Non-Executive Director赵倩ZHAO Qian
Executive Director胡会国HU Huiguo
Independent Non-Executive Director王芳WANG Fang
Executive Director桂勋GUI Xun

Major Shareholders

Major Shareholders & HoldingsAs of the Latest Practicable Date, Mr. Tang (i) directly owned approximately 79.92% of the partnership interest in Longrun Equity as a limited partner and indirectly owned 0.10% of the partnership interest in Longrun Equity through Longrun Investment Consulting as a general partner, and Longrun Equity beneficially owned 140,560,000 A Shares; (ii) directly owned approximately 2.12% of the partnership interest in Zhongjun Jianlong as a general partner, and Zhongjun Jianlong beneficially owned 20,000,000 A Shares; (iii) directly owned approximately 10.56% of the partnership interest in Zhenzhu Investment as a general partner, and Zhenzhu Investment beneficially owned 6,800,000 A Shares; and (iv) directly owned 88.30% of the equity interest in Longrun Investment Consulting, and Longrun Investment Consulting beneficially owned 2,000,000 A Shares. Under the Securities and Futures Ordinance, Mr. Tang is deemed to be interested in the shares held by Longrun Equity, Zhongjun Jianlong, Zhenzhu Investment, and Longrun Investment Consulting.
AI AI Analysis AI interpretation deepseek-v4-pro · AI-generated
!
The following content is generated by an AI model based on historical IPO data. It does NOT constitute investment advice, solicitation, or recommendation. Past subscription patterns and post-listing performance do not guarantee future results. Data may contain inaccuracies — always verify against official HKEX filings and prospectuses before making any investment decision.

Market Sentiment

The IPO of 迈威生物-B saw overwhelming retail enthusiasm with a 481.71x oversubscription ratio. Despite the high demand, the hit rate is reported as 0.0%, likely reflecting extremely low allocation under the no-clawback mechanism. This signals fierce competition for shares among small investors. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

Tier Analysis

At the A-Tail tier, 100,000 applicants expected just 0.3204 lots each, while the B-Head tier offered a full 1.0 lot per applicant for 200,000 applicants. This stark difference highlights an inefficiency where the marginal capital required to jump from A-Tail to B-Head dramatically improves allocation certainty. Broker fee efficiency likely favors larger applications, though actual costs vary. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

Demographics

Mainland Chinese participants accounted for 54.9% of total holders, indicating strong cross-border interest in this biotech listing. The investor base skews male (62.2%) with an average age of 43.2, typical for high-risk 18A biotech plays. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

About this page

This page shows Mabwell-B (02493) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect